3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
15
Prostatic Neoplasms
9
Colorectal Neoplasms
7
Ovarian Neoplasms
5
Endometrial Neoplasms
5
Colonic Neoplasms
5
Rectal Neoplasms
4
Colorectal Neoplasms, Hereditary Nonpolyposis
4
Pancreatic Neoplasms
3
Leukemia, Myeloid, Acute
3
Brain Neoplasms
3
Urogenital Neoplasms
2
Neoplastic Syndromes, Hereditary
2
Neoplasms, Unknown Primary
2
Neoplasm Metastasis
2
Leukemia, Myelomonocytic, Acute
2
Leukemia, Monocytic, Acute
2
Leukemia, Megakaryoblastic, Acute
2
Leukemia, Erythroblastic, Acute
2
Leukemia, Eosinophilic, Acute
2
Leukemia, Basophilic, Acute
2
Leukemia
2
Hereditary Breast and Ovarian Cancer Syndrome
2
Hematologic Neoplasms
2
Glioma
2
Carcinoma, Intraductal, Noninfiltrating
2
Women Age 35+ Qualifies if >15% Lifetime Risk of Breast Cancer as Defined by IBIS Version 8
1
Tuberous Sclerosis
1
Thyroid Neoplasms
1
Spinal Cord Neoplasms
1
Interventions
Trastuzumab
19
pyrotinib
14
pertuzumab
8
Docetaxel
7
Paclitaxel
6
Capecitabine
4
Carboplatin
3
neratinib
2
Protons
2
Neoadjuvant Therapy
2
Fulvestrant
2
Ado-Trastuzumab Emtansine
2
tucatinib
1
trastuzumab deruxtecan
1
pegfilgrastim
1
palbociclib
1
inavolisib
1
exemestane
1
envafolimab
1
dalpiciclib
1
atezolizumab
1
Taxoids
1
Metformin
1
Leuprolide
1
Letrozole
1
Isovaleryl-CoA Dehydrogenase
1
Goserelin
1
Genetic Testing
1
Fluorodeoxyglucose F18
1
Enfuvirtide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
HER2-positive Breast Cancer
×
Genetic Testing
×
Clear all
NCT04638725
2026-06-04
SIGHER
Centre Paul Strauss
Recruiting
9,000 enrolled